Recent Price Movement and Market Context
On 28 Nov 2025, Valiant Laboratories' share price touched an intraday low of Rs.66, representing the lowest level recorded in the past year and also an all-time low for the stock. The stock closed the day with a decline of 2.98%, underperforming its sector by approximately 3.5%. Over the last two trading sessions, the stock has recorded a cumulative return of -6.45%, reflecting a continued downward trend.
Intraday volatility was evident as the stock also reached a high of Rs.69.69, which was 2.44% above the previous close, before retreating to the low. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market index, Sensex, opened flat and traded marginally lower by 0.02% at 85,706.67 points. The Sensex remains close to its 52-week high of 86,055.86, trading above its 50-day and 200-day moving averages, indicating a generally bullish market environment that Valiant Laboratories has not mirrored.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Long-Term Performance and Valuation Metrics
Valiant Laboratories has experienced a notable decline over the past year, with its stock price showing a return of -43.64%, while the Sensex recorded a positive return of 8.43% during the same period. The stock’s 52-week high was Rs.136.80, indicating a near 52% reduction from that peak to the current low.
Over the last five years, the company’s operating profits have shown a compound annual growth rate (CAGR) of -49.92%, reflecting a contraction in core earnings. The average EBIT to interest ratio stands at 0.65, suggesting limited capacity to comfortably cover interest expenses from operating earnings. Return on equity (ROE) has averaged 0.80%, indicating modest profitability relative to shareholders’ funds.
Despite a recent ROE figure of 1.6%, the stock’s price-to-book value ratio is 1.2, which is considered relatively expensive compared to its peers’ historical valuations. This valuation is occurring even as the stock trades at a discount relative to the sector’s average historical multiples.
Profitability and Sales Trends
In the latest six-month period, Valiant Laboratories reported net sales of Rs.93.02 crores, reflecting a growth rate of 130.48%. Profit after tax (PAT) for the same period was Rs.2.02 crores, indicating a positive earnings trajectory in recent quarters. The company has declared positive results for three consecutive quarters, signalling some improvement in financial performance despite the stock’s price decline.
However, the company’s price-to-earnings-to-growth (PEG) ratio stands at 0.5, which may reflect the market’s cautious stance given the disparity between profit growth and stock price movement.
Shareholding and Sector Position
The majority shareholding in Valiant Laboratories is held by promoters, maintaining a concentrated ownership structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance across its constituents. While the broader sector has shown resilience, Valiant Laboratories has lagged behind both the sector and broader market indices.
Considering Valiant Laboratories ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Recent Trends and Market Positioning
Valiant Laboratories’ stock has been on a downward trajectory, reflected in its new 52-week low and underperformance relative to the Sensex and sector benchmarks. The stock’s trading below all major moving averages highlights the prevailing bearish momentum. Despite recent growth in sales and profits, the company’s long-term financial metrics indicate challenges in sustaining profitability and servicing debt efficiently.
The stock’s valuation metrics suggest a premium relative to book value, even as the market price has declined significantly over the past year. This juxtaposition points to a complex market assessment of the company’s prospects within the Pharmaceuticals & Biotechnology sector.
While the broader market indices maintain a generally positive stance, Valiant Laboratories remains an outlier with subdued price performance and valuation pressures.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
